The cyclooxygenase-2/prostaglandin E2 pathway is involved in the somatostatin-induced decrease of epileptiform...

Area of Science:

• Neuroscience
• Pharmacology
• Molecular Biology

Background:

• The neuromodulatory peptide somatostatin-14 (SRIF) inhibits epilepsy, but its signaling mechanisms are unclear.
• Epileptiform bursting in mouse hippocampal slices is a model for studying anti-epileptic actions.

Purpose of the Study:

• Investigate if the cyclooxygenase-2 (COX-2)/prostaglandin E2 (PGE2) pathway mediates SRIF's anti-epileptic effects.
• Determine the role of COX-2/PGE2 in epileptiform bursting.

Main Methods:

• Measured COX-2 expression (mRNA and protein) and PGE2 release during epileptiform bursting in mouse hippocampal slices.
• Utilized selective COX-2 inhibitors (NS-398, meloxicam) to assess their effects on bursting and PGE2 release.
• Administered SRIF and observed its impact on COX-2 expression, PGE2 release, and epileptiform bursting.

Main Results:

• Epileptiform bursting increased COX-2 expression and PGE2 release.
• COX-2 inhibition (NS-398, meloxicam) reduced PGE2 release and epileptiform bursting.
• SRIF counteracted the increase in COX-2 and PGE2, and comparably reduced bursting to NS-398 in a non-additive manner.
• PGE2 blocked SRIF's inhibitory effect on bursting.

Conclusions:

• The COX-2/PGE2 pathway promotes epileptiform bursting.
• SRIF exerts anti-epileptic effects by engaging the COX-2/PGE2 pathway.
• Identified key signaling events for SRIF's anti-convulsant action in hippocampal bursting models.